NEW YORK, Feb. 8,
2012/PRNewswire/ -- Keryx Biopharmaceuticals,
Inc. (Nasdaq: KERX) today announced that Ron
Bentsur, the Company's Chief Executive Officer,
will be presenting at the 14th Annual BIO CEO and Investor
Conference, which will be held at the Waldorf=Astoria Hotel
in New York City. Mr. Bentsur's
presentation is scheduled to take place on Tuesday,
February 14, 2012at 9:00 a.m. ET.
A live audio webcast of Mr. Bentsur's presentation will
be accessible from the Investor Information page of the
Company's Website at http://investors.keryx.com.
An archived version of the webcast will be available
following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition,
development and commercialization of medically important
pharmaceutical products for the treatment of cancer and
renal disease. Keryx is developing KRX-0401 (perifosine), a
novel, potentially first-in-class, oral anti-cancer agent
that inhibits Akt activation in the phosphoinositide
3-kinase (PI3K) pathway, and also affects a number of other
key signal transduction pathways, including the JNK
pathway, all of which are pathways associated with
programmed cell death, cell growth, cell differentiation
and cell survival. KRX-0401 is currently in Phase 3
clinical development for both refractory advanced
colorectal cancer and multiple myeloma, and in Phase 1 and
2 clinical development for several other tumor types. Each
of the KRX-0401 Phase 3 studies is being conducted under a
Special Protocol Assessment (SPA) agreement with the Food
and Drug Administration (FDA). Keryx is also developing
Zerenex (ferric citrate), an oral, ferric iron-based
compound that has the capacity to bind to phosphate and
form non-absorbable complexes. The Phase 3 clinical program
of Zerenex in the treatment for hyperphosphatemia (elevated
phosphate levels)FDA. Keryx is headquartered in New
York City.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
SOURCE Keryx Biopharmaceuticals, Inc.
